Interleukin-15: a new cytokine target for the treatment of inflammatory diseases.
Interleukin (IL)-15 is a pleiotropic pro-inflammatory cytokine that is expressed in several inflammatory disorders, including rheumatoid arthritis, psoriasis and pulmonary inflammatory diseases. IL-15 promotes activation of T cells, neutrophils and macrophages, and is critical to dendritic cell function in several model systems. Recent emerging data suggest that IL-15 may serve as a useful therapeutic target across a range of disease states. Advances in the past year highlight the beneficial effect of IL-15 neutralisation in models of psoriasis and diabetes. Further evidence for IL-15 expression and effector function has emerged across a range of rheumatic disorders, including juvenile inflammatory arthritis, rheumatoid arthritis and Kawasaki disease. These data hold promise for therapeutic targeting in ongoing human studies and those in the near future.
McInnes
Iain B
IB
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK. i.b.mcinnes@clinmed.gla.ac.uk
Gracie
J Alastair
JA
D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy; D006084:Graft Rejection; D006801:Humans; D007249:Inflammation / Q000628:therapy*; D019409:Interleukin-15 / Q000037:antagonists & inhibitors* / Q000502:physiology; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2 / Q000502:physiology
C508024:IL15RA protein, human; D019409:Interleukin-15; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2